Mammalian cells

US-Based Mammalian CDMO

cGMP Mammalian Cell Culture Manufacturing

Scorpius BioManufacturing is a boutique US-based CDMO offering mammalian clinical manufacturing services including cell culture process development, analytical development, and cGMP production for antibodies, vaccines, and therapeutic proteins.

At Scorpius we prioritize early-stage and small-volume programs and commit to giving your biologic the personalized attention and flexibility it deserves. We have dedicated ~5,400 sq. ft. of our facility to mammalian manufacturing in nine cGMP-compliant controlled cleanrooms with dedicated air handling units designed for maximal segregation. We offer cell culture development and manufacturing using CHO and HEK-293 cell expression systems.

 

US-Based Mammalian Cell Culture Services

 

As is the case with the rest of our facility, the cleanrooms prioritize American-made equipment and consumables, with many supplied mechanicals made on-site. The cleanroom areas in Scorpius' facility include mammalian cell culture incubators, bioreactors, cell harvesting systems, downstream filtration systems, and purification systems.

Our Mammalian CDMO Capabilities:

 

Icon_Mammalian Cells_Orange

 

Icon_Protein_Orange

 

Icon_Bioanalytical_Orange

 

Icon_Syringe Drug_Orange

 

Therapeutic
Proteins
Antibody
Production
Bioanalytical Services Vaccine Manufacturing

 

The controlled areas are designed for unidirectional flow of personnel, raw materials, intermediates, product, and waste. The material finishes used on the cleanroom walls, floors and ceilings were selected for ease of cleaning and are suited to cGMP-compliant biomanufacturing.

Scorpius BioManufacturing's cGMP-compliant mammalian cell culture facilities are equipped with bioreactors with capacities of 50, 200, 500 L, including the Pall Allegro™ STR single-use family of stirred tank bioreactors.

OUR BIOMANUFACTURING FACILITY:

 

 

Our easily scalable, single-use cell culture components and systems have been implemented as an alternative to cleanable, reusable systems. This approach results in process-specific benefits such as increased manufacturing flexibility, enhanced sterility assurance, elimination of cleaning and cleaning validation, reduced capital investment, faster processing times with increased productivity, and faster changeover to new product manufacture.

Want to know more about what Scorpius can do for your mammalian biomanufacturing project? Explore the capabilities at Scorpius' San Antonio facility